Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.57 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429100 | 1.00 | EPHX1 (0.59) | EPHX1MMP2ANPEPMAOACSNK1E | |
| SCHEMBL8629574 | 1.00 | EPHX1 (0.59) | EPHX1MMP2ANPEPMAOACSNK1E | |
| SCHEMBL8639910 | 1.00 | EPHX1 (0.59) | EPHX1MMP2ANPEPMAOACSNK1E | |
| Hydrochloric Acid SCHEMBL28198880 | 0.98 | EPHX1 (0.57) | EPHX1MMP2ANPEPMAOACSNK1E | |
| Hydrochloric Acid SCHEMBL28199429 | 0.98 | EPHX1 (0.57) | EPHX1MMP2ANPEPMAOACSNK1E | |
| SCHEMBL8713206 | 0.98 | EPHX1 (0.61) | EPHX1MMP2ANPEPMAOACSNK1E | |
| SCHEMBL28200559 | 0.92 | EPHX1 (0.64) | EPHX1MMP2ANPEPMAOASLC6A2 | |
| SCHEMBL10202821 | 0.92 | EPHX1 (0.64) | EPHX1MMP2ANPEPMAOASLC6A2 | |
| SCHEMBL9182651 | 0.92 | EPHX1 (0.70) | EPHX1MMP2ANPEPMAOACSNK1E | |
| SCHEMBL27295809 | 0.92 | EPHX1 (0.70) | EPHX1MMP2ANPEPMAOACSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10440955-B2 | Methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2018-05-10 | — | — | US | disclosed |
| US-9839219-B2 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | CURZA GLOBAL, LLC | 2016-11-17 | — | — | US | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMS, SMOX | EPHX1 2233/4885MMP2 235/4885ANPEP 568/4885 |
| US-10440955-B2 | Methods comprising a biocidal polyamine | SRM, SMOX, SMS | EPHX1 1994/4885MMP2 119/4885ANPEP 451/4885 |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | EPHX1 2010/4885MMP2 197/4885ANPEP 626/4885 |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | EPHX1 2010/4885MMP2 197/4885ANPEP 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.